US 12,169,199 B2
Activity based host cell protein profiling
Haibo Qiu, Hartsdale, NY (US); and Rosalynn Molden, Shoreline, WA (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 27, 2021, as Appl. No. 17/187,778.
Claims priority of provisional application 63/073,125, filed on Sep. 1, 2020.
Claims priority of provisional application 63/021,181, filed on May 7, 2020.
Claims priority of provisional application 62/982,346, filed on Feb. 27, 2020.
Prior Publication US 2021/0270824 A1, Sep. 2, 2021
Int. Cl. G01N 33/543 (2006.01); A61K 38/46 (2006.01); A61K 47/26 (2006.01); G01N 21/64 (2006.01); G01N 30/72 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/54306 (2013.01) [A61K 38/465 (2013.01); A61K 47/26 (2013.01); G01N 21/6428 (2013.01); G01N 30/7233 (2013.01); G01N 30/7266 (2013.01); G01N 33/6848 (2013.01); C12Y 301/01001 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A method of identifying host cell protein (HCP) impurities in a sample containing at least one high-abundance protein, the method comprising:
contacting the sample with at least one probe capable of attaching to a HCP impurity, wherein the probe includes a warhead and a tag, and wherein the warhead is capable of binding to an active site of the probe-attached HCP impurity;
contacting the sample with a solid support, wherein the solid support comprises a ligand, and wherein the ligand is capable of binding to the tag; and
washing the solid support using a solution to provide an eluent to isolate the probe-attached HCP impurity.